With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.879-65-2,2-Quinoxalinecarboxylic acid,as a common compound, the synthetic route is as follows.,879-65-2
Example 99N-((ls,4s)-4-(2-(4′-(2-((3S,5R)-3,5-dimethylpiperazin-l-yl)ethyl)biphenyl-3-yloxy)-5- fluoronicotinamido)cyclohexyl)quinoxaline-2-carboxamide Step (a) N-((l s,4s)-4-(5-fluor o-2-(3-iodophenoxy)nicotinamido)cyclohexyl)quinoxaline-2- carboxamideTo a suspension of N-((ls,4s)-4-aminocyclohexyl)-5-fluoro-2-(3-iodophenoxy Nicotinamide (2.56 g, 5.21 mmol) in acetonitrile (100 niL) was added quinoxaline-2-carboxylic acid (0.907 g, 5.21 mmol) and triethylamine (7.26 mL, 52.06 mmol). On addition of triethylamine the reaction mixture became a homogeneous solution. 1-Propanephosphonic acid cyclic anhydride, 1.57M solution in THF (3.48 mL, 5.47 mmol) was then added and the mixture stirred at RT for 2 h. The mixture was evaporated to dryness and the residue dissolved in DCM (150 mL) and washed with saturated NaHCCh (aq), brine, dried (MgSO4) and evaporated to give the sub-title compound as a light brown foam. Yield: 3.08 g 1H NMR (400 MHz, CDCl3) delta 9.67 (s, IH), 8.37 (dd, J= 8.1, 3.2 Hz, IH), 8.22 – 8.18 (m, IH), 8.11 – 8.07 (m, 2H), 7.95 (d, J= 6.9 Hz, IH), 7.91 – 7.85 (m, 3H), 7.64 – 7.59 (m, IH), 7.59 – 7.56 (m, IH), 7.20 – 7.14 (m, 2H), 4.33 – 4.24 (m, IH), 4.24 – 4.13 (m, IH), 2.07 – 1.82 (m, 6H), 1.80 – 1.67 (m, 2H). MS: [M+H]+ = 612 (MultiMode+).
As the paragraph descriping shows that 879-65-2 is playing an increasingly important role.
Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2009/144494; (2009); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider